CD19 CART Long Term Follow Up (LTFU) Study

Patients are enrolled following completion or early discontinuation from a Novartis sponsored
or supported study of CD19 directed CAR T-Cell treatment and will be followed for 15 years
post treatment from the last CD19 directed CAR T-Cell treatment. Patients will be monitored
for safety and efficacy within the primary treatment protocols for the protocol defined
duration. While every effort will be made to keep patients in follow-up within the respective
treatment protocol itself, patients can drop off treatment protocols at any time. Patients
discontinuing from the primary treatment protocols for any reason will be enrolled in this
long term follow up (LTFU). This will allow collecting data on long term safety and efficacy
(as applicable) as mandated by the health authorities of all patients treated with CD19 CART
therapy within the concept of a single protocol.

Collection of such long term effects of CD19 CART cell therapy will help to further define
the risk-benefit profile of CD19 CART.

Inclusion Criteria:

- All patients who have received anti-CD19 directed CART therapy and completed or
discontinued early from a Novartis sponsored treatment protocol that utilized
CD19-directed CART cells or from any CD19 CART trial sponsored by the University of
Pennsylvania with which Novartis has a contractual agreement to co-develop the CAR
technology.

- Patients who have provided informed consent for the long term follow up study prior to
their study participation .

Exclusion Criteria:

- There are no specific exclusion criteria for this study.